PT  - JOURNAL ARTICLE
AU  - Giuseppe Santini
AU  - Stefano Di Carlo
AU  - Alfredo Benso
AU  - Nadia Mores
AU  - Paul Brinkman
AU  - Salvatore Valente
AU  - Paolo Montuschi
AU  - Francesco Macagno
AU  - Gianfranco Politano
AU  - Ariane H. Wagener
AU  - Aruna T. Bansal
AU  - Hugo H. Knobel
AU  - Anton J. Vink
AU  - Nicholas Rattray
AU  - Marco Santonico
AU  - Giorgio Pennazza
AU  - Yuanyue Wang
AU  - Ildiko Horvath
AU  - Ratko Djukanovic
AU  - Riccardo Polosa
AU  - Stephen J. Fowler
AU  - Pascal Chanez
AU  - Kian F. Chung
AU  - Peter J. Sterk
AU  - Paolo Montuschi
AU  - U-BIOPRED Study Group
TI  - Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults
AID  - 10.1183/13993003.congress-2015.OA1463
DP  - 2015 Sep 01
TA  - European Respiratory Journal
PG  - OA1463
VI  - 46
IP  - suppl 59
4099  - http://erj.ersjournals.com/content/46/suppl_59/OA1463.short
4100  - http://erj.ersjournals.com/content/46/suppl_59/OA1463.full
SO  - Eur Respir J2015 Sep 01; 46
AB  - Rationale: Omalizumab, an anti-IgE monoclonal antibody, is indicated in adults with severe persistent allergic asthma. Exhaled molecular markers can provide phenotypic information in asthma.Objectives: Determine whether adults with severe asthma on omalizumab (anti-IgE+) have a different breathprint compared with those who were not on anti-IgE therapy (anti-IgE-) as assessed by eNoses and gas chromatography/mass spectrometry (GC/MS) (breathomics).Methods: This was a cross-sectional analysis of the U-BIOPRED adult cohort. Severe asthma was defined by IMI-criteria [Bel, Thorax 2011]. Anti-IgE+ patients were on a regular treatment with s.c. omalizumab (150-375 mg) every 2-4 weeks. Exhaled volatile compounds trapped on adsorption tubes were analysed by a centralized eNose platform (Owlstone Lonestar, two Cyranose 320, Comon Invent, Tor Vergata TEN), including a total of 190 sensors, and GC/MS. Recursive feature elimination (http://topepo.github.io/caret/rfe.html) was used for feature selection and random forests, more robust to overfitting, for classification.Results: 9 anti-IgE+ (females/males 2/7, age 52.6±16.3 years, mean±SD, 1/2/6 current/ex/nonsmokers, pre-bronchodilator FEV1 70.6±21.1% predicted value) and 30 anti-IgE- patients (18/12 females/males, age 53.2±14.2 years, 0/16/14 current/ex/nonsmokers, pre-bronchodilator FEV1 59.6±30.7% predicted value) were studied. Accuracy of classification is shown in Table 1.View this table:Table 1 Conclusions: Preliminary results suggest that breathomics can distinguish between anti-IgE+ and anti-IgE- severe asthma patients.